Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas

British Journal of Cancer

Volumn 88, Issue 9, 2003, Pages 1403-1405

  Edmunds, S C ^a,b   Cree, I A ^b,c   Di Nicolantonio F ^b,c   Hungerford, J L ^d   Hurren, J S ^b   Kelsell, D P ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

BRAF; DNA sequence; Melanoma; Mutation

Indexed keywords

ANTINEOPLASTIC AGENT; BRAF INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAF GENE; CANCER CELL CULTURE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG DESIGN; EXON; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SKIN CANCER; UVEA MELANOMA;

EID: 0038146846     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600919     Document Type: Article

References (21)

1. Albert DM, Niffenegger AS, Willson JK (1992) Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 36: 429-438
2. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997-7000
3. Chin L, Merlino G, DePinho RA (1998) Malignant melanoma: modern black plague and genetic black box. Genes Dev 12: 3467-3481
4. Chow S, Patel H, Hedley DW (2001) Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 46: 72-78
5. Coudert B, Anthoney A, Fiedler W, Droz JP, Dieras V, Borner M, Smyth JF, Morant R, de Vries MJ, Roelvink M, Fumoleau P (2001) Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group Report. Eur J Cancer 37: 2194-2198
6. Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, McIntosh LW, Geary RS, Eisenhauer EA (2002) Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Clin Cancer Res 8: 2188-2192
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
8. Demunter A, Ahmadian MR, Libbrecht L, Stas M, Baens M, Scheffzek K, Degreef H, De Wolf-Peeters C, van Den Oord JJ (2001) A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res 61: 4916-4922
9. Dolin PJ, Foss AJ, Hungerford JL (1994) Uveal melanoma: is solar ultraviolet radiation a risk factor? Ophthalmic Epidemiol 1: 27-30
10. Edmunds SC, Kelsell DP, Hungerford JL, Cree IA (2002) Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. Invest Ophthalmol Vis Sci 43: 2845-2851
11. Mooy CM, Van der Helm MJ, Van der Kwast TH, De Jong PT, Ruiter DJ, Zwarthoff EC (1991) No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited. Br J Cancer 64: 411-413
12. Naus NC, Zuidervaart W, Rayman N, Slater R, van Drunen E, Ksander B, Luyten GP, Klein A (2000) Mutation analysis of the PTEN gene in uveal melanoma cell lines. Int J Cancer 87: 151-153
13. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS (2003) High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20
14. Pollock PM, Meltzer PS (2002) A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2: 5-7
15. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347: 1222-1225
16. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934
17. Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ (2001) Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 7: 1214- 1220
18. Seftor RE, Seftor EA, Hendrix MJ (1999) Molecular role(s) for integrins in human melanoma invasion. Cancer Metast Rev 18: 359-375
19. Sisley K, Parsons MA, Garnham J, Potter AM, Curtis D, Rees RC, Rennie IG (2000) Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma. Br J Cancer 82: 330-338
20. Soparker CN, O'Brien JM, Albert DM (1993) Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. Invest Ophthalmol Vis Sci 34: 2203-2209
21. Soufir N, Bressac-de Paillerets B, Desjardins L, Levy C, Bombled J, Gorin I, Schlienger P, Stoppa-Lyonnet D (2000) Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes. Br J Cancer 82: 818-822